RxDoctor Payments Data

Ruth Dwyer

Family · Martinsville, INNPI 1184850562

Payments from drug & device makers

$1,350in general payments, 2019–2025

Across 18 payments — averaging $75.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$606
  • AstraZeneca$399
  • Bayer$125
  • Biohaven Pharmaceutical Holding Company Ltd.$114
  • Edwards Lifesciences$45
  • Boston Scientific$29
  • plus $32 from 2 others

What the payments were for

  • Food & beverage$1,33899%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,350 in reported general payments places this provider in the 70th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$55,059
Medicare patients
188
Services billed
10,210

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide51$89,257
Trelegy ElliptaFluticasone/Umeclidin/Vilanter80$89,028
EliquisApixaban82$81,391
JardianceEmpagliflozin38$49,206
Breztri AerosphereBudesonide/Glycopyr/Formoterol33$28,741
TrulicityDulaglutide14$28,705
XareltoRivaroxaban15$25,229
MounjaroTirzepatide13$19,572
Breo ElliptaFluticasone/Vilanterol32$16,823
Tresiba Flextouch U-100Insulin Degludec12$8,950
Albuterol Sulfate HfaAlbuterol Sulfate245$6,683
SymbicortBudesonide/Formoterol Fumarate20$4,562
Atorvastatin Calcium421$4,071
Omeprazole185$3,591
Celecoxib71$3,420

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$606$89,25751 claims
Lilly USA, LLCTrulicity, Mounjaro$12$48,27727 claims
AstraZenecaBreztri Aerosphere, Symbicort$399$33,30353 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,392 family providers in Indiana.

Other family in Martinsville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →